Teva Parkinson's Agent Azilect Will Launch Within 10 Weeks
This article was originally published in The Pink Sheet Daily
Executive Summary
Partner Eisai will continue to co-develop the MAO-B inhibitor for Alzheimer's disease, but it is "still considering" whether it will opt to co-promote the agent for Parkinson's.